This article has Open Peer Review reports available.
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
- Dimitrios Pectasides1Email author,
- George Papaxoinis1,
- Konstantine T Kalogeras2, 3,
- Anastasia G Eleftheraki4,
- Ioannis Xanthakis2,
- Thomas Makatsoris5,
- Epaminondas Samantas6,
- Ioannis Varthalitis7,
- Pavlos Papakostas8,
- Nikitas Nikitas9,
- Christos N Papandreou10,
- George Pentheroudakis11,
- Eleni Timotheadou2,
- Angelos Koutras5,
- Joseph Sgouros6,
- Dimitrios Bafaloukos12,
- George Klouvas13,
- Theofanis Economopoulos14,
- Konstantinos N Syrigos15 and
- George Fountzilas2
© Pectasides et al.; licensee BioMed Central Ltd. 2012
Received: 4 September 2011
Accepted: 29 June 2012
Published: 29 June 2012
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting firstname.lastname@example.org.
|4 Sep 2011||Submitted||Original manuscript|
|14 Jan 2012||Reviewed||Reviewer Report - Lara Lipton|
|4 Apr 2012||Reviewed||Reviewer Report - Wei Chua|
|6 May 2012||Author responded||Author comments - George Papaxoinis|
|Resubmission - Version 2|
|6 May 2012||Submitted||Manuscript version 2|
|29 Jun 2012||Editorially accepted|
|29 Jun 2012||Article published||10.1186/1471-2407-12-271|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting email@example.com. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.